LITTLE ROCK — Some people who use so-called synthetic marijuana, known by names such as K2 and Spice, may be unable to metabolize the drug, leading them to experience its most harmful effects, a UAMS researcher said today at a national scientific meeting in Chicago.
Anna Radominska-Pandya, Ph.D., part of a UAMS research team examining how the body processes the man-made cannabinoids, presented the team’s findings on the harmful effects of synthetic marijuana at the American Society for Pharmacology and Experimental Therapeutics annual meeting held during the Experimental Biology 2017 meeting that draws thousands.
Synthetic “marijuana” is a growing group of man-made cannabinoids marketed as alternatives to marijuana. Although the man-made drugs activate the same receptors in the brain as natural marijuana, they are known to have volatile effects that can lead to severe injury and death.
Radominska-Pandya is a professor in the UAMS College of Medicine Departments of Biochemistry and Molecular Biology and Medicine. Her work could identify genetic risk factors that make some people susceptible to the synthetic cannabinoids’ most harmful consequences, potentially leading to antidotes that counteract the worst effects.
Radominska-Pandya and her colleagues have found that some people are unable to metabolize and excrete synthetic cannabinoids. They now hypothesize that a person’s genetic makeup could produce the metabolism defects that cause the most harmful effects from the drug. Future genetics tests could potentially identify those people.
“It is important to understand the underlying causes and toxicity of synthetic cannabinoids so that effective treatments and antidotes can be developed,” Radominska-Pandya said.
UAMS has been a national leader of synthetic cannabinoid research since the UAMS Translational Research Institute funded the team’s work in 2011 with a $100,000 pilot award. In 2016, the team, led by Paul Prather, Ph.D., a professor in the Department of Pharmacology and Toxicology, received a five-year, $2.7 million National Institute of Drug Abuse grant that builds on the work of the pilot study.
Synthetic cannabinoids come in more than 150 chemical forms and the list is growing. As new synthetic cannabinoids appear on the market, the UAMS research team will study their properties and how the body’s metabolism may contribute to their harmful effects.
Experimental Biology is an annual meeting comprised of more than 14,000 scientists and exhibitors from six host societies and multiple guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the United States and the world who represent dozens of scientific areas, from laboratory to translational to clinical research.
UAMS is the state’s only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; a hospital; a northwest Arkansas regional campus; a statewide network of regional centers; and seven institutes: the Winthrop P. Rockefeller Cancer Institute, the Jackson T. Stephens Spine & Neurosciences Institute, the Myeloma Institute, the Harvey & Bernice Jones Eye Institute, the Psychiatric Research Institute, the Donald W. Reynolds Institute on Aging and the Translational Research Institute. It is the only adult Level 1 trauma center in the state. UAMS has 2,870 students, 799 medical residents and five dental residents. It is the state’s largest public employer with more than 10,000 employees, including about 1,200 physicians who provide care to patients at UAMS and its regional campuses throughout the state, Arkansas Children’s Hospital, the VA Medical Center and Baptist Health. Visit www.uams.edu or www.uamshealth.com. Find us on Facebook, Twitter, YouTube or Instagram.